The practical implication is that these adaptive EGFR-mutant lung cancer cells that survive erlotinib in escape would also evade detection by clinical 18FDG-PET scanning due to their suppressed glucose metabolism, forming therefore the basis of radiographic complete response (CR) or near-CR despite the presence of minimal residual tumor disease in therapeutic escape. The gene discussed is EGFR; the disease is lung cancer.